Tiziana life sciences ltd (“tiziana” or “the company”) - interim results for the six months ended 30 june 2022

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

TLSA Ratings Summary

TLSA Quant Ranking